Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy - PubMed (original) (raw)
Review
Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy
T Harkany et al. Rev Neurosci. 2000.
Abstract
One of the characteristic neuropathological hallmarks of Alzheimer's disease (AD) is the extracellular accumulation of beta-amyloid peptides (Abeta) in neuritic plaques. Experimental data indicate that different molecular forms of Abeta affect a wide array of neuronal and glial functions and thereby may lead to neuronal death in the nervous system. Whereas the fatal outcome of Abeta overproduction in transgenic cell lines, and of exogenous Abeta administration in numerous neurotoxicity models, is well established, particular facets of a complex molecular cascade by which Abeta attack neural cells are still elusive. In the present review we summarize recent knowledge on mechanisms of Abeta aggregation, its role in Abeta neurotoxicity, and binding of Abeta peptides to putative neuronal and glial receptors. Additionally, an integrative view on the interactions of Ca2+ -mediated excitotoxicity and free radical-induced oxidative stress in Abeta toxicity is provided. Furthermore, we survey advances of pharmacological investigations attempting to prevent and antagonize Abeta toxicity, or to promote neuronal regeneration following Abeta-induced neurotoxic insults. We distinguish two major classes of therapeutic approaches: conventional pharmacotherapy that employs blockade of known receptors, signal transduction pathways, and re-uptake of neurotransmitters, and direct targeting of neurotoxic Abeta by means of beta-sheet breakers, functional anti-Abeta peptides, and antibodies. Although a clinically relevant neuroprotective strategy is not yet available, sequential combination of drug regimens may provide prospects for effective antagonism of late-life Abeta burden and subsequent development of dementia.
Similar articles
- Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity.
Sturchler E, Galichet A, Weibel M, Leclerc E, Heizmann CW. Sturchler E, et al. J Neurosci. 2008 May 14;28(20):5149-58. doi: 10.1523/JNEUROSCI.4878-07.2008. J Neurosci. 2008. PMID: 18480271 Free PMC article. - Alzheimer's disease.
De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. De-Paula VJ, et al. Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Subcell Biochem. 2012. PMID: 23225010 Review. - Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: relevance to Alzheimer's disease.
Harkany T, Hortobágyi T, Sasvári M, Kónya C, Penke B, Luiten PG, Nyakas C. Harkany T, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1999 Aug;23(6):963-1008. doi: 10.1016/s0278-5846(99)00058-5. Prog Neuropsychopharmacol Biol Psychiatry. 1999. PMID: 10621945 Review. - Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review.
Butterfield DA. Butterfield DA. Free Radic Res. 2002 Dec;36(12):1307-13. doi: 10.1080/1071576021000049890. Free Radic Res. 2002. PMID: 12607822 Review.
Cited by
- Neuroprotective effects of LMW and HMW FGF2 against amyloid beta toxicity in primary cultured hippocampal neurons.
Cheng Y, Li Z, Kardami E, Loh YP. Cheng Y, et al. Neurosci Lett. 2016 Oct 6;632:109-13. doi: 10.1016/j.neulet.2016.08.031. Epub 2016 Aug 18. Neurosci Lett. 2016. PMID: 27546824 Free PMC article. - Glial cell dysregulation: a new perspective on Alzheimer disease.
von Bernhardi R. von Bernhardi R. Neurotox Res. 2007 Dec;12(4):215-32. doi: 10.1007/BF03033906. Neurotox Res. 2007. PMID: 18201950 Review. - The renaissance of Ca2+-binding proteins in the nervous system: secretagogin takes center stage.
Alpár A, Attems J, Mulder J, Hökfelt T, Harkany T. Alpár A, et al. Cell Signal. 2012 Feb;24(2):378-387. doi: 10.1016/j.cellsig.2011.09.028. Epub 2011 Oct 1. Cell Signal. 2012. PMID: 21982882 Free PMC article. Review. - The role of gonadotropins in Alzheimer's disease: potential neurodegenerative mechanisms.
Barron AM, Verdile G, Martins RN. Barron AM, et al. Endocrine. 2006 Apr;29(2):257-69. doi: 10.1385/ENDO:29:2:257. Endocrine. 2006. PMID: 16785601 Review. - The degradation of amyloid beta as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses.
Morelli L, Llovera R, Ibendahl S, Castaño EM. Morelli L, et al. Neurochem Res. 2002 Nov;27(11):1387-99. doi: 10.1023/a:1021679817756. Neurochem Res. 2002. PMID: 12512943 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous